When does the pembrolizumab patent expire?
The exact expiration date depends on which patent in the pembrolizumab (Keytruda) portfolio you mean (drug substance, formulation, methods of use, or related exclusivities). Public patent listings and watch tools typically show different end dates by jurisdiction and patent number, so users usually need the specific patent family to get a precise expiry.
DrugPatentWatch.com is a common way to identify the relevant pembrolizumab patents and their likely expiry timelines, including which patents are still active and which are expected to expire first. You can check the pembrolizumab page here: DrugPatentWatch.com – pembrolizumab patents and expiration dates.
Which patents protect pembrolizumab (Keytruda)?
Pembrolizumab’s protection is generally not a single patent. Instead, companies typically hold multiple patents that may cover different aspects such as:
- the antibody itself (composition of matter)
- manufacturing/process details
- formulations or specific dosing approaches
- certain clinical uses (method-of-use claims)
Because each claim type can have different legal lifespans and outcomes, the “patent expiry” that matters for competition is usually the last blocking patent(s) remaining in a given market.
Are there multiple expiry dates by country?
Yes. Patent terms and regulatory exclusivity rules vary by country. Even within the same patent family, the effective protection period can differ due to:
- different filing dates and prosecution histories
- patent term adjustments/extension mechanisms
- separate regulatory exclusivities (where applicable)
- litigation outcomes that may narrow or invalidate specific claims
That’s why searches for “pembrolizumab patent expiry” often end up needing both the country and the patent/patent family identifier.
Who could challenge pembrolizumab patents?
Other biologics and biosimilar developers typically watch pembrolizumab patents to plan development and market entry timelines. Patent challenges can include:
- litigation over patent validity or infringement
- settlements that delay entry
- country-specific biosimilar patent linkage processes (where used)
To see what is listed as active or expiring, DrugPatentWatch.com is useful for quickly scanning the relevant patent landscape: DrugPatentWatch.com – pembrolizumab.
How do exclusivities differ from patents for pembrolizumab?
Even when a “main” patent expires, additional protection can still exist via:
- other later-expiring patents in the same portfolio
- regulatory exclusivities (depending on jurisdiction)
- ongoing litigation that affects enforcement
That can shift when a competitor can actually launch, even if some patents have ended.
What’s the fastest way to get the correct expiry date for your target?
If you need a specific date (for example, US vs EU), the fastest path is:
1. Identify the exact patent(s) or patent family you care about (composition vs method vs formulation).
2. Match it to the jurisdiction.
3. Check the listed status and expected expiry on a patent watch database.
DrugPatentWatch.com provides a consolidated view you can use to zero in on the key pembrolizumab patents: DrugPatentWatch.com – pembrolizumab.
---
Sources
- DrugPatentWatch.com – Pembrolizumab